Orthocell was granted a European Patent titled “Culture medium, culturing method and use of tenocytes,” covering the manufacture of tenocytes used to form the Ortho-ATI® Autologous Tenocyte Implantation product.
Orthocell’s tendon repair applications such as Ortho-ATI, Ortho-ACI® and CelGro® have been granted patent protection in Australia, China, the EU, Hong Kong, New Zealand, Singapore and the U.S.
In late 3Q17, Orthocell announced enrollment of the first patient in a randomized, controlled clinical trial of Ortho-ATI vs. corticosteroid injection to treat rotator cuff tendinopathy. The trial is a collaboration between Orthocell and DePuy Synthes.
Orthocell was granted a European Patent titled "Culture medium, culturing method and use of tenocytes," covering the manufacture of tenocytes used to form the Ortho-ATI® Autologous Tenocyte Implantation product.
Orthocell’s tendon repair applications such as Ortho-ATI, Ortho-ACI® and CelGro® have been granted patent protection in Australia,...
Orthocell was granted a European Patent titled “Culture medium, culturing method and use of tenocytes,” covering the manufacture of tenocytes used to form the Ortho-ATI® Autologous Tenocyte Implantation product.
Orthocell’s tendon repair applications such as Ortho-ATI, Ortho-ACI® and CelGro® have been granted patent protection in Australia, China, the EU, Hong Kong, New Zealand, Singapore and the U.S.
In late 3Q17, Orthocell announced enrollment of the first patient in a randomized, controlled clinical trial of Ortho-ATI vs. corticosteroid injection to treat rotator cuff tendinopathy. The trial is a collaboration between Orthocell and DePuy Synthes.
Copy to clipboard 
